To MMP or not to MMP: a role for matrix metalloproteinase 3 in primary sclerosing cholangitis?

摘要

The second part of the paper is dedicated to the development of strategies for greater availability of antiviral therapy for HBV infection in order to decrease morbidity and mortality. Taking into account the limited economic resources, the use of drugs should be prioritized for patients with cirrhosis or HIV/HBV coinfec-tion. The panel also recommends the use of tenofovir and entecavir as first-line treatment, given their high genetic barrier, and suggests avoiding the use of lamivudine, emtricitabine and telbivudine as single agents because of the objective impracticality of monitoring and managing the emergence of viral mutants.